BMY
REPL
ASCO comes with a little stock sparkle
Replimune showed up to ASCO with final Phase 1 data for RP2, its oncolytic immunotherapy, and the market immediately started acting like it had found a new favorite biotech plotline. Shares jumped about 7% in premarket trading on Monday as investors digested the readout.
The headline number: RP2 monotherapy posted an objective response rate of 19.0% in evaluable patients, while the combo with Bristol-Myers Squibb's Opdivo (nivolumab) came in at 19.1%. Not exactly a moonshot, but in biotech, even modest-looking response data can be enough to make traders lean in and start squinting at the slide deck like it’s the latest season finale.
Why investors care
This wasn’t just a one-line data dump. Replimune said the treatment showed tumor regression in both injected and non-injected lesions, which is the kind of detail that hints at a systemic immune response — biotech’s favorite phrase when it wants to sound like the body is doing something impressively complicated on purpose.
The company also highlighted its earlier RP1 plus nivolumab data in anti-PD-1 failed melanoma, where median overall survival hit 32.9 months and the three-year survival rate was 47.8% across all treated patients.
The fine print still matters
Before you start imagining victory laps, remember the usual biotech caveat: these are still clinical data, not a regulatory green light. Replimune is fighting for credibility in a space where one good conference presentation can lift the stock — and one bad FDA decision can drag it right back down.
Big picture: the market likes a clean catalyst, and ASCO delivered one. But for REPL, the real question is whether these encouraging snapshots can eventually turn into a durable approval story, not just a nice Monday bounce.